From an experimental model to a recovery claim
A later, larger study helps put an early signal in context.
LL-37: following a clinical question.
A later, larger study helps put an early signal in context.
Read the later study
Mahlapuu and colleagues published a phase IIb trial in 2021 involving 148 participants with hard-to-heal venous ulcers. It compared topical LL-37 with placebo, alongside compression. The full-population analysis did not identify a statistically significant healing improvement with LL-37. That finding belongs alongside any mention of the initial 2014 work.
Which conclusion to retain
Absence of a significant difference does not establish equivalence or settle every subgroup hypothesis. It also cannot transfer a venous-ulcer signal to every tissue. Retain the population, background care and primary analysis; present exploratory hypotheses as new questions.
Professional context / Contexto profesional
Funded by Promore Pharma; several authors had company affiliations. Full conflict and protocol appraisal pending.
Evidence / Evidencia
Phase IIb randomized clinical trial.
Limitations / Limitaciones
Historical selection, not a systematic LL-37 review or a treatment recommendation.